Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies directed against only one target that leads to resistance, highlight the need for new approaches. Classical natural killer T (NKT) cells engineered to express CARs constitute a novel type of allogeneic therapy that does not require T-cell receptor (TCR) gene editing, thus avoiding graft-vs.-host disease (GVHD).